HR+
Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer
Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial
Actionable Insights Powered by AI
Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial